Universal Health Services CEO was highest-paid hospital leader in 2016

If you were judging hospital executives by their pay, the winner would Alan Miller, MBA, chairman and CEO of Pennsylvania-based Universal Health Services (UHS), who earned $51.3 million in 2016.

That’s according to Axios, which based the title off his base salary, gains on stocks and options, incentive compensation and payment for perks and personal benefits detailed in the company’s annual proxy filing with the Securities and Exchange Commission (SEC). It’s a separate methodology than an earlier Axios report which compared hospital CEOs based on how much they’re paid per patient day.

Miller’s high level of compensation isn’t surprising considering he founded the company and has held the CEO and chairman titles ever since, along with being its president until 2009. That title now belongs to his son, Marc, who made $7.2 million last year.

“The Compensation Committee, in determining Mr. Alan Miller’s compensation, takes into account his position as chief executive office , his role as a founder of our company in 1978, his years of dedicated service and his expertise and reputation in the hospital management industry,” the proxy filing said. “The Compensation Committee also considers Mr. Alan Miller’s responsibilities in overseeing all of our company’s businesses, operations, development and overall strategy and his role as the public face of our Company, which shapes our corporate image and identity. These factors differentiate Mr. Alan Miller from the other named executive officers.”

The filing said Miller’s compensation was above the 75th percentile for groups made up of his peers and the hospital industry in general, but it also noted the median tenure for other CEOs was 5.2 years, far below Miller’s 38.

UHS also had a successful year financially in 2016, reporting net income of $702 million on revenues of $9.8 billion, an improvement on 2015 net income of $680.5 million on revenues of $9 billion.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.